Abstract
The goal of this study was to evaluate independent risk factors for long-term epistaxis recurrences and their severity. Individual retrospective cohort study-2b level of evidence. The medical information of 603 emergency epistaxis patients was acquired during a former study. This cohort has been contacted 6 years later by conventional mail and asked to answer a specific paper questionnaire. The following parameters were evaluated: recurrent epistaxis episodes, need for a surgical intervention to stop the recurrent bleeding, patient’s history for hypertension and diabetes, intake of hemostasis impairing medication now and in the past. One hundred and six (106) patients were included in the study (35.8 % response rate). The mean observation period was 76.58 months. Almost half of the patients (41.5 % = 44/106) reported at least one recurrent epistaxis episode. Patients with exposure to VKA (vitamin K antagonists) showed significantly more frequently a recurrent epistaxis episode. The binary logistic regression confirmed the intake of VKA as an independent and significant risk factor with an odds ratio of 11.6. Every single patient who had to undergo a surgical intervention to stop a recurrent bleeding stated ASA (Acetylsalicylic Acid) intake. We provide evidence that the intake of a vitamin K antagonist is an independent long-term risk factor for recurrent epistaxis episodes. The intake of ASA is a risk factor for the severity of recurrent epistaxis with the increased need for a surgical intervention not only in a short- but also in a long-term perspective.
Level of evidence
This prognostic investigation, designed as a combined prospective and retrospective cohort study, reaches level 2b level of evidence as it includes retrospective aspects.
Similar content being viewed by others
References
Villwock JA, Jones K (2013) Recent trends in epistaxis management in the United States: 2008–2010. JAMA Otolaryngol Head Neck Surg 139(12):1279–1284
Soyka MB, Nikolaou G, Rufibach K, Holzmann D (2011) On the effectiveness of treatment options in epistaxis: an analysis of 678 interventions. Rhinology 49(4):474–478
Verheugt FW, Granger CB (2015) Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet
Melia L, McGarry GW (2011) Epistaxis: update on management. Curr Opin Otolaryngol Head Neck Surg 19(1):30–35
Kemal O, Sen E (2014) Does the weather really affect epistaxis? B-ENT 10(3):199–202
Herkner H, Laggner AN, Müllner M, Formanek M, Bur A, Gamper G et al (2000) Hypertension in patients presenting with epistaxis. Ann Emerg Med 35(2):126–130
Soyka MB, Schrepfer T, Holzmann D (2012) Blood markers of alcohol use in epistaxis patients. Eur Arch Oto-Rhino-Laryngol: Off J Eur Fed Oto-Rhino-Laryngol Soc 269(8):1917–1922
Melia L, McGarry G (2008) Epistaxis in adults: a clinical review. Br J Hosp Med (Lond) 69(7):404–407
Soyka MB, Rufibach K, Huber A, Holzmann D (2010) Is severe epistaxis associated with acetylsalicylic acid intake? Laryngoscope 120(1):200–207
Kindler RM, Holzmann D, Landis BN, Ditzen B, Soyka MB (2015) The high rate of long-term recurrences and sequelae after epistaxis treatment. Auris Nasus Larynx. doi:10.1016/j.anl.2015.09.011
Soyka MB, Holzmann D (2013) Should we test the prothrombin time in anticoagulated epistaxis patients? Allergy Rhinol (Providence) 4(1):e52–e53
Benninger MS, Marple BF (2004) Minor recurrent epistaxis: prevalence and a new method for management. Otolaryngol Head Neck Surg 131(3):317–320
Ando Y, Iimura J, Arai S, Arai C, Komori M, Tsuyumu M et al (2014) Risk factors for recurrent epistaxis: importance of initial treatment. Auris Nasus Larynx 41(1):41–45
Denholm SW, Maynard CA, Watson HG (1993) Warfarin and epistaxis—a case controlled study. J Laryngol Otol 107(3):195–196
Abrich V, Brozek A, Boyle TR, Chyou PH, Yale SH (2014) Risk factors for recurrent spontaneous epistaxis. Mayo Clin Proc 89(12):1636–1643
Tay HL, Evans JM, McMahon AD, MacDonald TM (1998) Aspirin, nonsteroidal anti-inflammatory drugs, and epistaxis. A regional record linkage case control study. Ann Otol Rhinol Laryngol 107(8):671–674
Cingoz F, Oz BS, Arslan G, Guler A, Sahin MA, Gunay C et al (2014) Is chronic obstructive pulmonary disease a risk factor for epistaxis after coronary artery bypass graft surgery? Cardiovasc J Afr 25(6):279–281
Terakura M, Fujisaki R, Suda T, Sagawa T, Sakamoto T (2012) Relationship between blood pressure and persistent epistaxis at the emergency department: a retrospective study. J Am Soc Hypertens 6(4):291–295
Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS et al (2012) Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging 5(3 Suppl):S62–S72
Lubianca Neto JF, Fuchs FD, Facco SR, Gus M, Fasolo L, Mafessoni R et al (1999) Is epistaxis evidence of end-organ damage in patients with hypertension? Laryngoscope 109(7 Pt 1):1111–1115
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors state that there are no conflicts of interest to disclose. There are no financial disclosures.
Rights and permissions
About this article
Cite this article
Stadler, R.R., Kindler, R., Holzmann, D. et al. The long-term fate of epistaxis patients with exposure to antithrombotic medication. Eur Arch Otorhinolaryngol 273, 2561–2567 (2016). https://doi.org/10.1007/s00405-016-3913-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-016-3913-9